Incentives for Research, Development, and Innovation in Pharmaceuticals

ISBN-13: 9788493806217 / Angielski / Miękka / 2012 / 96 str.

Walter A. Garcia-Fontes

Opis

Incentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement different measures that promote research in these less profitable areas. This book describes how incentives can be provided to deal with less profitable activities when no clear markets exist for the innovations. The book discusses alternative mechanisms to substitute for inexistent markets, situations where traditional instruments have proven totally insufficient, and the clear mismatch between the size of the markets being targeted and the incentives being provided. Patents become an ineffective way to incentivise R&D when the appropriability is low; this book provides alternative ideas such as allowing for a period of data exclusivity to firms that develop new drugs.

Spis treści

Introduction.- Incentives for innovation: a survey.- Incentives for innovation: neglected diseases.- When patents are not enough: supplementary incentives for pharmaceutical innovation.- The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003.- The use of pay for performance for drugs: can it improve incentives for innovation?.- Drug Price Regulation: Recent Trends and Downstream Neglected Issues.

O autorze

Walter Garcia-Fontes is an associate professor at the Department of Economics and Business of Universitat Pompeu Fabra. His research interests are in Industrial Organization, firm innovation, technological change and applied econometrics. He has published his work in leading international field journals. He has coordinated various projects in the European Commission Framework Programmes studying the European chemical industry and the organizational changes related to new industrial relations.

Blurb

Incentives for innovation are particularly relevant in the pharmaceutical

industry where not all social needs provide equally profitable

opportunities and where most OECD countries try to implement diffe -

rent measures that promote research in these less profitable areas. The

lack of incentives for innovation is especially dramatic when we take

into account diseases affecting mostly low-income countries, and also

diseases affecting small groups of patients.

How can incentives be provided to deal with these less profitable acti -

vities when no clear markets exist for the innovations being introduced?

Some of the contributions of this book go into discussing alternative

mechanisms to substitute for these inexistent markets, and

situations where traditional instruments such as public procurement or

direct subsidies have proven totally insufficient. Also, this book discusses

the clear mismatch between the size of the markets being targeted and

the incentives being provided.